Category: 2017

September | 2017

Cannabics Pharmaceuticals Files National Phase Applications for Its System and Method for High Throughput Screening of Cancer Cells

TEL AVIV, Israel, September 25, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) today announced it has filed national phase patent a

September | 2017

Cannabics Pharmaceuticals Files a Patent Application for Sensitivity Tests of Cannabinoids on Patient Derived Tumor Biopsies and CTCs

TEL-AVIV, Israel, September 6, 2017 Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has filed an extensive provisional patent a

August | 2017

Cannabics Pharmaceuticals Received Positive Report from The Patent Cooperation Treaty Regarding Cannabinoid Personalized Screening of Cancer Cells

TEL-AVIV, Israel, August 28, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) (OTCQB: CNBX) today announced it received a very positive prel

July | 2017

Cannabics Pharmaceuticals Establishes a Human-Cannabis-Cancer Genetics lab to Expand its Personalized Diagnostics

Cannabics Pharmaceuticals Inc. (OTC-QB: CNBX) today announced it has established a Genetic lab that will develop diagnostic tools based on human genom

July | 2017

Cannabics Pharmaceuticals Executed a Final Collaboration Agreement with SIMFO GmbH

Cannabics Pharmaceuticals Inc. (CNBX) today announced it has executed a Collaboration Agreement with SIMFO GmbH, a world leader in cancer diagnostics

June | 2017

Cannabics Pharmaceuticals Receives Positive Results in Drug Sensitivity Tests on CTCs

Cannabics Pharmaceuticals Inc. (CNBX) today announced it received positive results from screening necrosis (cell death) of circulating tumor cells, fr

June | 2017

Cannabics Pharmaceuticals Inc. Provides Shareholders Update June 2017

Cannabics Pharmaceuticals Inc. (OTC-QB: CNBX) today Provides Shareholders Update for June 2017: Cannabis has the potential of being a natural

May | 2017

Cannabics Pharmaceuticals Raises $3,000,000 in Capital Raise Transaction

Cannabics Pharmaceuticals Inc. (CNBX) today announced it has entered into a securities purchase agreement with D-Beta One EQ, Ltd. ("D-Beta"). D-Beta

May | 2017

Cannabics Pharmaceuticals Announces Scientific Collaboration With A Leading CTC European Lab

TEL AVIV, Israel, May 3, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) today announced it has begun a scientific collaboration with a med

April | 2017

Cannabics Pharmaceuticals Inc. Receives the Final Report of Its Research on Antitumor Properties of Cannabinoids Held in Israel

TEL AVIV, Israel, April 3, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) is pleased to announce that it received the final report of the

March | 2017

Cannabics Pharmaceuticals Inc. Appoints New Members to its Board of Advisors

Cannabics' Pharmaceutical (CNBX) Board of Directors is proud to announce its addition of several highly-respected professionals to its Board of Adviso

February | 2017

Cannabics Pharmaceuticals Inc. Provides Shareholders Update Regarding Increased Volume in its Shares

BETHESDA, Maryland, Feb. 23, 2017 /PRNewswire/ -- The management of Cannabics Pharmaceuticals Inc. (CNBX) wishes to inform its shareholders and public

February | 2017

Cannabics Pharmaceuticals Announces Initial Commercialization of Cannabinoids-based Personalized Diagnostics for Cancer Patients

BETHESDA, Maryland, Feb. 6, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) today announced it will begin providing personalized can

January | 2017

Cannabics Pharmaceuticals Announces a New Dosage of 5mg THC Cannabis Capsule Treating Cancer Patients Suffering from Cachexia and Anorexia Syndrome

BETHESDA, Maryland, Jan. 3, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) today announced development of Cannabics 5mg THC Capsule intend